nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin
|
Kattan, Joseph |
|
2018 |
130 |
C |
p. 60-69 |
artikel |
2 |
Biomarkers of response to immune checkpoint blockade in cancer treatment
|
Fujii, Takeo |
|
2018 |
130 |
C |
p. 108-120 |
artikel |
3 |
Clinical update on K-Ras targeted therapy in gastrointestinal cancers
|
Pant, Shubham |
|
2018 |
130 |
C |
p. 78-91 |
artikel |
4 |
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis
|
Bringhen, Sara |
|
2018 |
130 |
C |
p. 27-35 |
artikel |
5 |
Editorial Board
|
|
|
2018 |
130 |
C |
p. IFC |
artikel |
6 |
Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer
|
Liang, Fei |
|
2018 |
130 |
C |
p. 36-43 |
artikel |
7 |
GEORCC recommendations on target volumes in radiotherapy for Head Neck Cancer of Unkown Primary
|
Cabrera Rodríguez, Joaquín |
|
2018 |
130 |
C |
p. 51-59 |
artikel |
8 |
Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists
|
Stein, Alexander |
|
2018 |
130 |
C |
p. 13-26 |
artikel |
9 |
Role of vena cava filters for the management of cancer-related venous thromboembolism: Systematic review and meta-analysis
|
Rojas-Hernandez, Cristhiam Mauricio |
|
2018 |
130 |
C |
p. 44-50 |
artikel |
10 |
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy
|
Russo, A. |
|
2018 |
130 |
C |
p. 1-12 |
artikel |
11 |
The use of SAMe in chemotherapy-induced liver injury
|
Vincenzi, B. |
|
2018 |
130 |
C |
p. 70-77 |
artikel |
12 |
Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies
|
Martin, Antony P. |
|
2018 |
130 |
C |
p. 92-107 |
artikel |